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Background: Long-term outcomes of partial liver resection of hepatocellular carcinoma (HCC) remain satisfactory
due to high incidences of recurrence. This study was intended to see whether preoperative transcatheter arterial
chemoembolization (TACE) reduces postoperative tumor recurrences and prolongs survival of patients with
resectable HCC.
Methods: A computerized literature search was performed to identify relevant articles. The quality of
nonrandomized comparative studies (NRCTs) was assessed using the methodological index for nonrandomized
studies (MINORS). Data synthesis was performed using Review Manager 5.0 software.
Results: Twenty-one studies (4 randomized controlled trials and 17 NRCTs) with a total of 3,210 participants were
suitable for analysis. There was no significant difference in disease-free and overall survival at 5-year (32.1% vs.
30.0% and 40.2% vs. 45.2%), and intra- and extra-hepatic recurrence (51.2% vs.53.6% and 12.9% vs.10.3%) between
patients with and without preoperative TACE. Postoperative morbidity (28.9% vs. 26.8%) and in-hospital mortality
(4.1% vs. 3.1%) were also similar between the two groups.
Conclusions: Preoperative TACE does not seem to improve prognosis and therefore it is prudent to recommend it
as a preoperative routine procedure for resectable HCC.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide, and ranks the third leading
cause of cancer-related death [1]. Hepatectomy is consid-
ered the main curative treatment for HC with a 5-year
survival of 23.8–54.8% as reported in the most recent
series [2-5]. Tumor recurrence even after radical surgery
affects 75-100% HC patients, accounting for the major
cause of death of HC patients [6]. The development of
appropriate strategies to prevent tumor recurrence is* Correspondence: Binl1962@yahoo.com.cn
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reproduction in any medium, provided the ortherefore critical for improving long-term outcomes of
HC patients after surgical resection.
Transcatheter arterial chemoembolization (TACE), which
induces tumor ischemic necrosis by arterial injection
of chemotherapeutic drugs and embolizing agents, is
recommended as the first-line palliative treatment for
inoperable HCC in the 2005 practice guidelines issued
by the American Association for the Study of Liver
Diseases [7]. Some researchers believed that it may reduce
the viability of HCC cells before surgery and reduce post-
operative tumor recurrence [8]. Although several studies
have demonstrated the survival benefits of preoperative
TACE for patients with HCC [9,10], others have failed to
show any significant survival benefit [11-16]. Therefore,
the role of preoperative TACE for HCC remains a contra-
dictory issue. A recent review of three randomizedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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did not significantly improve survival [17]. However, their
study only involved 257 participants, and therefore may
not be convincing enough to confirm the effect conclu-
sively [18]. To produce more reliable evidence for clinical
decision-making, meta-analytic techniques could be ap-
plied to nonrandomized comparative studies (NRCTs) to
ensure both the number and sample size of RCTs [19],
knowing that meta-analysis of well-designed NRCTs is
feasible and the results are remarkably similar to those of
contemporaneous RCTs [20]. The present meta-analysis
should be able to provide an updated evaluation on pre-
operative TACE for resectable HCC by taking into account
all the currently evidence from RCTs and well-designed
NRCTs.Methods
Inclusion and exclusion criteria
The present meta-analysis was performed by following
the recommendations of the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
Statement. Primary studies that evaluated the efficacy of
preoperative TACE vs. no-preoperative TACE for resect-
able HCC were considered for inclusion. For duplicate
publications reported by the same authors, either the
one of higher quality or the most recent publication was
selected. Abstracts, letters, editorials and expert opin-
ions, reviews without original data, case reports, and
uncontrolled studies were excluded. Study populations
including recurrent HCC or unresectable diseases were
also excluded.Study selection
A computerized search of the literature was performed by
searching Medline, EMBASE, OVID, and Cochrane data-
base from the time of inception to June 2012. The following
medical subject heading (MeSH) terms were used: “hepa-
tectomy,” “hepatocellular carcinoma,” and “transarterial
chemoembolization”. Only studies on humans and in the
English language were considered for inclusion. Reference
lists of all identified articles were manually searched for
additional studies. Publication bias was assessed visually
using a funnel plot.Data extraction
Two reviewers (LW and YZ) independently extracted the
following parameters from each study: first author, year of
publication, study population characteristics, study design,
inclusion and exclusion criteria, the number of subjects in
each arm, survival, recurrence, morbidity and mortality.
All relevant texts, tables and figures were reviewed for
data extraction.Qualitative analysis
The RCTs were scored using the Jadad composite scale
[21], which evaluates studies based on appropriate
randomization, double blinding, and an adequate descrip-
tion of withdrawals and drop-outs. For evaluation of
NRCTs, the methodological index for nonrandomized
studies (MINORS) with some modifications were applied
[22]. The following 12 items were evaluated for each
study: a clearly stated aim, consecutive patients, prospect-
ive data collection, reported endpoints, unbiased outcome
evaluation, adequate length of follow-up, loss to follow up
<5%, ≥ 20 patients in each arm, adequate control group,
contemporary groups, controls equivalent to cases, and
adequate statistical analyses. Studies achieving more than
16 points (maximum 24) were defined as well-designed
and were included in the meta-analysis [20]. Those with
less than 16 points were excluded.
Outcomes of interests
Items for assessing long-term outcomes included disease-
free and overall survival rate at 5 year, total recurrence,
hepatic recurrence, and extrahepatic recurrence.
Items for assessing short-term outcomes included
postoperative morbidity and in-hospital mortality.
Statistical analysis and synthesis
Dichotomous variables were tested by odds ratio (OR)
with a 95% confidence interval (95% CI), and continuous
variables were tested by the weighted mean difference
(WMD) with a 95% CI. Between-study heterogeneity was
evaluated by χ2 and I2. Data that were not significantly het-
erogeneous (P > 0.1) were calculated using a fixed effects
model, and heterogeneous data (P < 0.1) were calculated
using a random-effects model. Sensitivity analysis was
undertaken by using the following subgroups: (1) RCTs,
(2) NRCTs, and (3) studies with matched clinicopathologi-
cal parameters. Statistical analyses were performed with
Review Manager version 5.0 (The Cochrane Collaboration,




Twenty-six studies that matched the selection criteria
were retrieved from the electronic databases [9-16,23-41].
Of these studies, one study was excluded due to overlap of
authors and nonrandomized nature [23], and therefore
the most recent RCT was included [24]. Four NRCTs with
fewer than 16 points were excluded [9,25-27]. Finally, 21
articles, including four RCTs [14-16,24] and 17 NRCTs
[10-13,28-40], met the inclusion criteria.
The characteristics of the 21 studies are summarized in
Table 1. A total of 3,210 patients were included in the
meta-analysis, of whom 1,431 received preoperative TACE
Table 1 Clinical background of studies included in the meta-analysis
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Figure 1 Funnel plot analysis of publication bias. The outcome
was the 5-year disease-free survival.
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of patients in each study varied from 40 to 350 patients. In
the enrolled patients, the percentage of men ranged from
76.9% to 100% and the mean age ranged from 45.3 ± 9.8
to 68.1 ± 5.7 years. Eight studies were completely matched
with respect to the reported clinicopathological parame-
ters [12,15,16,28,30,32,35,39]. One trial was conducted to
compare outcomes of whole-liver TACE, selective TACE,
and without preoperative TACE [24]. Only selective TACE
arm was considered in the present meta-analysis.
The data regarding the effects of TACE on tumor re-
sponses were available in 18 studies [10-16,24,28,30-38],Table 2 Results of overall meta-analysis
Outcomes No. of studies No.of pa
TACE (+
Long-term outcomes
5-years disease-free survival 18[10,11,13-16,24,28,31-40] 1275
5-years overall survival 16[11,12,14-16,24,28,29,31,34-40] 1038
Total recurrence 11[10,14,16,24,30,32,35,36,38-40] 673
Intrahepatic recurrence 12[10-12,14,16,24,29,30,32,35,36,39] 660
Extrahepatic recurrence 9[10,14,16,24,30,32,35,36,39] 519
Short-term outcomes
Overall morbidity 11[10-12,14,16,24,29,30,35,36,40] 583
Liver failure 6[11,12,14,16,29,36] 337
Bile leakage 6[12,14,16,29,35,36] 371
Pleural effusion 4[12,29,35,36] 300
Ascites 3[29,35,36] 269
Intra-abdominal abscess 5[11,14,29,35,36] 348
Wound infection 5[12,14,16,35,36] 311
Postoperative bleeding 3[11,12,36] 206
Stress ulcer bleeding 3[12,29,35] 180
Pneumonia 4[11,12,14,35] 199
Mortality 16[10-12,14-16,24,28-30,33-36,38,40] 1100
HG heterogeneity.in which histological examination on surgical speci-
mens revealed that a total of 260 patients (20.1%) of
1,292 patients had complete tumor necrosis ranging from 0
to 53.6%.
The funnel plot (Figure 1) for 5-year disease-free
survival in the included studies demonstrated asymmetry,
indicating an insignificant sign of publication bias.
Overall meta-analysis
The results from overall meta-analysis are summarized
in Table 2.
Long-term outcomes
The 5-year disease-free survival was 7.0–57% for pre-
operative TACE and 8.0–48.8% for control in 18 studies
[10,11,13-16,24,28,31-40]. The 5-year overall survival was
15.4–62.7% for preoperative TACE and 19.0–62.5% for
control in 16 studies [11,12,14-16,24,28,29,31,34-40].
Pooled analyses showed that preoperative TACE use
was not associated with significant improvement in
disease-free and 5-year overall survival (32.1% vs. 30.0%,
P = 0.17; 40.2% vs. 45.2%, P = 0.37, respectively). There
was significant heterogeneity between studies reporting
these two outcomes (P = 0.02, P < 0.01; respectively)
(Figures 2, 3).
Eleven studies reported on total recurrence after surgery:
411 61.0%) of 673 with preoperative TACE vs.536 (58.4%)
of 917 without TACE [10,14,16,24,30,32,35,36,38-40].tients Results OR (95% CI) P
value
HG
p value) TACE (−) TACE (+) TACE (−)
1567 32.1% 30.0% 1.19 (0.93, 1.53) 0.17 0.02
1463 40.2% 45.2% 0.85 (0.59, 1.22) 0.37 <0.01
917 61.0% 58.4% 0.99 (0.72, 1.36) 0.95 0.08
797 51.2% 53.6% 0.84 (0.67, 1.05) 0.12 0.23
591 12.9% 10.3% 1.30 (0.88, 1.92) 0.19 0.33
803 28.9% 26.8% 1.02 (0.80, 1.32) 0.85 0.42
457 5.9% 6.3% 1.06 (0.57, 1.96) 0.86 0.31
569 3.5% 2.8% 1.12 (0.53, 2.35) 0.77 0.80
485 7.0% 8.0% 0.93 (0.53, 1.65) 0.24 0.26
378 6.3% 6.1% 0.98 (0.51, 1.89) 0.96 0.16
451 2.5% 1.3% 1.66 (0.63, 4.40) 0.31 0.58
501 3.2% 2.5% 1.11 (0.48, 2.53) 0.81 0.35
305 3.3% 2.9% 1.25 (0.41, 3.81) 0.69 0.63
332 1.1% 1.2% 1.31 (0.29, 5.92) 0.73 0.74
337 4.0% 2.1% 1.64 (0.60, 4.46) 0.33 0.23
1325 4.1% 3.1% 1.25 (0.80, 1.97) 0.33 0.85
Figure 2 Results of the meta-analysis on 5-year disease-free survival.
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between the two groups (P = 0.95). There was moderate
heterogeneity between studies (P = 0.08).
Further pooled analysis of studies providing information
found that the percentages of both intra- and extrahepatic
recurrence were also similar in the two groups (51.2%
vs.53.6%, P = 0.12; 12.9% vs. 10.3%, P = 0.19, respectively).
No significant heterogeneity was detected between the
groups in reporting these two outcomes (Figures 4, 5).
Short-term outcomes
Eleven studies reported on overall morbidity: 169
(28.9%) of 583 with preoperative TACE vs. 216 (26.8%)
of 803 without TACE [10-12,14,16,24,29,30,35,36,40].
Pooled analyses showed that the difference was insig-
nificant between the two groups (P =0.85) without
significant heterogeneity (Figure 6). Further subanalysis
showed that the risk was comparable between patients
in both study groups with respect to liver failure (5.9% vs.
6.3%, P =0.86), bile leakage (3.5% vs. 2.8%, P =0.77),
pleural effusion (7.0% vs. 8.0%, P =0.24), ascites (6.3% vs.Figure 3 Results of the meta-analysis on 5-year overall survival.6.1%, P =0.96), intra-abdominal abscess (2.5% vs. 1.3%,
P =0.31), wound infection (3.2% vs. 2.5%, P =0.81), post-
operative bleeding (3.3% vs. 2.9%, P =0.69), stress ulcer
bleeding (1.1% vs. 1.2%, P =0.73), and pneumonia (4.0%
vs. VS. 2.1%, P =0.33).
Sixteen studies reported on in-hospital mortality
[10-12,14-16,24,28-30,33-36,38,40], showing that 87
patients died: 46 in the preoperative TACE group and
41 in the control group. Pooled analyses showed that
there was no statistical difference between the two
groups (P =0.33) (Figure 7).
Sensitivity analysis
As Table 3 shows, the results of sensitivity analysis
derived from three subgroups were all consistent with
those derived from overall meta-analysis.
Discussion
The design of TACE is based on the principle that
primary HCC is supplied almost exclusively (90%) by
the hepatic arteries. The obstruction of the feeding
Figure 4 Results of the meta-analysis on intrahepatic recurrence.
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bination of chemotherapy can drastically increase the
local concentration of the chemotherapeutic agent and
may improve the benefit of therapy. In 2003, a review
of 7 RCTs showed that TACE significantly improved
2-year overall survival compared with nonactive treat-
ment in patients with unresectable HCC [41]. In 2005,
this therapy was recommended as standard interven-
tion for unresectable patients with large/multifocal
HCC who do not have vascular invasion or extrahe-
patic spread [7]. In contrast, the results of present
pooled analysis of 21 trials do not support the use of
preoperative TACE in the management of patients with
resectable HCC.
Although TACE is effective for main tumors, intra-
hepatic metastases, tumor thrombi in the portal veins,
and capsular invasion, which are considered risk factors
contributing to HCC recurrence, are more unresponsive
to TACE because of collateral and portal vein blood
supply [8,13,16]. In addition, TACE mainly affects well-
differentiated HCC without completely killing poorly
differentiated cells [42], which harbour a high grade of
malignancy and ready spread within the portal venous
system [43]. Furthermore, hematogeneous and lymph-
atic spread dissemination of cancer cells can precede
TACE treatment. It is therefore reasonable to conclude
that TACE is unable to reduce the risk of postoperative
recurrence, or confer a survival advantage.Figure 5 Results of the meta-analysis on extrahepatic recurrence.Adachi et al. [13] and Harada et al. [28] reported that
the TACE subgroup with complete tumor necrosis had a
better survival rate than the group without TACE. This is
partly due to residual confounding, because tumors with
complete necrosis are strongly associated with favorable
tumor-related factors, such as smaller tumor size and
tumor encapsulation or less portal involvement. On the
other hand, several other reports failed to make the same
conclusion [15,28,30,31]. It was found in the present study
that approximately 20.1% of HCC tumors responded com-
pletely to TACE, suggesting that most of the HCC tumor
cells were viable even when treated with TACE. The label-
ing index of proliferating cell nuclear antigen (a most
widely used proliferation-associated marker) was signifi-
cantly higher in the TACE group, indicating that residual
HCC cells following preoperative TACE exhibit more
aggressive behavior [44]. In support of this observation,
Liou et al. [45] indicated that incomplete HCC necrosis
after TACE (especially combined with necrotic area >50%
main tumor size) was associated with the development of
lung metastasis that has a strong adverse impact on
patient survival. Adachi et al. [13] and Kim et al. [37]
found that subjects with partial tumor necrosis had
the lowest disease-free survival rate among the TACE
subgroups and tended to have a lower survival rate than
the group without TACE. Zhou et al. [16] noted that five
patients lost the chance of potentially curative liver resec-
tion because of progression of disease with metastases
Figure 6 Results of the meta-analysis on overall morbidity.
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last TACE hepatic resection. The mechanism underlying
accelerated tumor progression by TACE is unclear.
Intratumoral necrosis was found to weaken the adhesive
potential of the tumor and subsequently facilitate the re-
lease of cancer cells from the primary tumor and dislodg-
ment into the bloodstream [46]. Xiao et al. [47] reported
that mutated p53 could enhance the proliferation of HCC
cells and suppress the apoptosis of HCC cells after TACE.
In addition, vascular endothelial growth factor (VEGF),
the most specific known angiogenic factor that plays a
critical role in tumor growth, invasion, and metastasis,
was up-regulated by tumor tissue ischemia and hypoxia
after TACE [48].
In the present meta-analysis, in-hospital mortality did
not differ significantly between TACE group patients
and non-TACE group patients. However, Gerunda et al.
[25] reported that three patients died of liver failure
during 2–5 months after surgery in the TACE group.
Sasaki et al. [34] and Uchida et al. [29] reported that
late death due to liver failure was significantly higher in
the TACE group than that in the non-TACE group.
Uchida et al. [29] considered that hepatic function
impairment induced by TACE could be repaired easilyFigure 7 Results of the meta-analysis on in-hospital mortality.in the noncirrhotic liver, but hepatic function may gra-
dually and progressively deteriorate due to TACE in
some cirrhotic patients.
This study has several limitations. First, much of the
evidence comes from NRCTs that could either exagge-
rate or underestimate the measured magnitude of effect
size [20]. To minimize this effect, we limited the
analysis to well-designed studies. As a matter of fact,
the estimates from overall meta-analysis were consistent
with those derived from RCTs, suggesting that the mag-
nitude of the effect was not affected by the inclusion of
NRCTs. Second, significant heterogeneity was present
in some outcomes. Variability in the surgeon experience
and the chemoembolization schedule may have intro-
duced potential bias. In addition, clinicopathological
factors associated with recurrence, such as hepatitis
status, cirrhotic liver, and tumor staging, might be
another source of potential heterogeneity. The use of
random-effects models partially mitigates this concern.
Third, although 21 studies involving more than 3,000
patients were enrolled for analysis, funnel plot analysis
revealed the sign of publication bias. This may relate to
the use of published English data only. Fourth, it is
important to note that 18 of the 21 studies were from
Table 3 Results of sensitivity analysis
Outcome No. of studies No.of patients Results OR (95% CI) P value HG
p valueTACE (+) TACE (−) TACE (+) TACE (−)
RCTs
5-years disease-free survival 4[14-16,24] 167 172 29.3% 31.9% 0.85 (0.53, 1.39) 0.52 0.16
5-years overall survival 4[14-16,24] 167 172 36.5% 38.3% 0.89 (0.56, 1.41) 0.61 0.11
Total recurrence 3[14,16,24] 116 124 74.1% 74.2% 1.03 (0.36, 2.90) 0.96 0.07
Intrahepatic recurrence 3[14,16,24] 116 124 50.0% 46.7% 1.32 (0.47, 3.70) 0.59 0.02
Extrahepatic recurrence 3[14,16,24] 116 124 28.4% 22.5% 1.37 (0.42, 4.43) 0.60 0.04
Overall morbidity 3[14,16,24] 113 127 20.3% 21.2% 0.97 (0.52, 1.82) 0.93 0.14
Mortality 4[14-16,24] 163 174 3.1% 4.0% 0.70 (0.22, 2.30) 0.56 0.95
NRCTs
5-years disease-free survival 14[10,11,13,28,31-40] 1108 1395 32.4% 29.8% 1.28 (0.98, 1.67) 0.07 0.04
5-years overall survival 12[11,12,28,29,31,34-40] 871 1291 40.9% 46.1% 0.86 (0.55, 1.32) 0.48 <0.01
Total recurrence 8[10,30,32,35,36,38-40] 559 795 58.1% 55.8% 0.98 (0.77, 1.25) 0.86 0.11
Intrahepatic recurrence 9[10-12,29,30,32,35,36,39] 546 675 51.2% 56.5% 0.79 (0.62, 1.01) 0.06 0.84
Extrahepatic recurrence 6[10,30,32,35,36,39] 403 467 8.4% 7.0% 1.22 (0.73, 2.06) 0.44 0.74
Overall morbidity 8[10-12,29,30,35,36,40] 470 676 31.0% 27.9% 1.03 (0.79, 1.36) 0.81 0.50
Mortality 12[10-12,28-30,33-36,38,40] 937 1151 4.3% 2.9% 1.39 (0.85, 2.28) 0.19 0.74
Studies with complete matched clinicopathological parameters
5-years disease-free survival 6[15,16,28,32,35,39] 421 404 26.8% 22.0% 1.13 (0.62, 2.05) 0.69 0.02
5-years overall survival 7[12,15,16,28,32,35,39] 452 511 44.6% 35.2% 1.15 (0.76, 1.74) 0.50 0.08
Total recurrence 5[16,30,32,35,39] 297 349 73.7% 76.5% 0.91 (0.62, 1.33) 0.64 0.15
Intrahepatic recurrence 6[12,16,30,32,35,39] 328 456 56.4% 60.1% 0.81 (0.59, 1.11) 0.20 0.69
Extrahepatic recurrence 5[16,30,32,35,39] 297 349 13.1% 9.4% 1.40 (0.83, 2.38) 0.21 0.80
Overall morbidity 4[12,16,30,35] 191 344 36.1% 28.2% 1.36 (0.91, 2.01) 0.13 0.48
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http://www.biomedcentral.com/1471-230X/13/51Asia. This may raise a question regarding the validity of
the results and applicability to other areas. Finally,
although some authors have reported the efficacy of
preoperative TACE for patients with advanced HCC
[33] and large HCC [31,40], the results are not further
estimable for subgroup analysis given the absence of
data in this respect in the other studies.Conclusions
The updated meta-analysis represents the largest body
of information currently available for assessing the role
of preoperative TACE for HCC. This study demon-
strates that preoperative TACE does not seem to im-
prove the prognosis and therefore it should be prudent
to recommend it as a preoperative routine procedure
for resectable HCC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YZ participated in the design and coordination of the study, carried out the
critical appraisal of studies and wrote the manuscript. LW, FY, XZ, and XS
developed the literature search, carried out the extraction of data, assisted in
the critical appraisal of included studies and assisted in writing up. LS,YZ, and
BL carried out the statistical analysis of studies. All authors read and
approved the final manuscript.
Acknowledgements
We thank Doctor Yanfang Zhao (Department of Health Statistics, Second
Military Medical University, Shanghai, China) for her critical revision of the
meta-analysis section.
Author details
1Department of Hepatobiliary & Pancreatovascular Surgery, First affiliated
Hospital of Xiamen University; Oncologic Center of Xiamen, Xiamen, China.
2Department IV of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital,
Second Military Medical University, Shanghai 200438, China.
Received: 11 August 2012 Accepted: 12 March 2013
Published: 19 March 2013
References
1. Forner A, Hessheimer AJ, Isabel Real M, et al: Treatment of hepatocellular
carcinoma. Crit Rev Oncol Hematol 2006, 60:89–98.
2. Katz SC, Shia J, Liau KH, et al: Operative blood loss independently predicts
recurrence and survival after resection of hepatocellular carcinoma.
Ann Surg 2009, 249:617–623.
3. Fan ST, Mau Lo C, Poon RT, et al: Continuous improvement of survival
outcomes of resection of hepatocellular carcinoma: a 20-year
experience. Ann Surg 2011, 253:745–758.
4. Zhou Y, Sui C, Li B, et al: Safety and efficacy of trisectionectomy for
hepatocellular carcinoma. ANZ J Surg 2011, 81:895–899.
5. Shrager B, Jibara G, Schwartz M, et al: Resection of hepatocellular
carcinoma without cirrhosis. Ann Surg 2012, 255:1135–1143.
6. Tung-Ping Poon R, Fan ST, Wong J: Risk factors, prevention, and
management of postoperative recurrence after resection of
hepatocellular carcinoma. Ann Surg 2000, 232:10–24.
7. Bruix J, Sherman M: Practice guidelines committee. American association
for the study of liver diseases. Management of hepatocellular carcinoma.
Hepatology 2005, 42:1208–1236.
8. Higuchi T, Kikuchi M, Okazaki M: Hepatocellular carcinoma after
transcatheter hepatic arterial embolization. A histopathologic study of
84 resected cases. Cancer 1994, 73:2259–2267.9. Imaoka S, Sasaki Y, Shibata T, et al: A pre-operative chemoembolization
therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular
carcinoma. Cancer Chemother Pharmacol 1989, 23:S126–S128.
10. Majno PE, Adam R, Bismuth H, et al: Influence of preoperative transarterial
lipiodol chemoembolization on resection and transplantation for
hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997,
226:688–701.
11. Di Carlo V, Ferrari G, Castoldi R, et al: Pre-operative chemoembolization of
hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology
1998, 45:1950–1954.
12. Nagasue N, Galizia G, Kohno H, et al: Adverse effects of preoperative
hepatic artery chemoembolization for resectable hepatocellular
carcinoma: a retrospective comparison of 138 liver resections.
Surgery 1989, 106:81–86.
13. Adachi E, Matsumata T, Nishizaki T, et al: Effects of preoperative
transcatheter hepatic arterial chemoembolization for hepatocellular
carcinoma. The relationship between postoperative course and tumor
necrosis. Cancer 1993, 72:3593–3598.
14. Wu CC, Ho YZ, Ho WL, et al: Preoperative transcatheter arterial
chemoembolization for resectable large hepatocellular carcinoma: a
reappraisal. Br J Surg 1995, 82:122–126.
15. Yamasaki S, Hasegawa H, Kinoshita H, et al: A prospective randomized trial
of the preventive effect of pre-operative transcatheter arterial
embolization against recurrence of hepatocellular carcinoma.
Jpn J Cancer Res 1996, 87:206–211.
16. Zhou WP, Lai EC, Li AJ, et al: A prospective, randomized, controlled trial of
preoperative transarterial chemoembolization for resectable large
hepatocellular carcinoma. Ann Surg 2009, 249:195–202.
17. Wang X, Li J, Peng Y, et al: Influence of preoperative transarterial
chemoembolization on the prognosis for patients with resectable
hepatocellular carcinoma: a meta-analysis of randomized trials.
Hepatogastroenterology 2011, 58:869–874.
18. Rerkasem K, Rothwell PM: Meta-analysis of small randomized controlled
trials in surgery may be unreliable. Br J Surg 2010, 97:466–469.
19. Mathurin P, Raynard B, Dharancy S, et al: Meta-analysis: evaluation of
adjuvant therapy after curative liver resection for hepatocellular
carcinoma. Aliment Pharmacol Ther 2003, 17:1247–1261.
20. Abraham NS, Byrne CJ, Young JM, et al: Meta-analysis of well-designed
nonrandomized comparative studies of surgical procedures is as good
as randomized controlled trials. J Clin Epidemiol 2010, 63:238–245.
21. Jadad AR, Moore RA, Carroll D, et al: Assessment the quality of reports of
randomized clinical trials: is blinding necessary? Control Clin Trials 1996,
17:1–12.
22. Slim K, Nini E, Forestier D, et al: Methodological index for non-randomized
studies (minors): development and validation of a new instrument.
ANZ J Surg 2003, 73:712–716.
23. Kaibori M, Tanigawa N, Matsui Y, et al: Influence of transcatheter arterial
chemoembolization on the prognosis after hepatectomy for
hepatocellular carcinoma in patients with severe liver dysfunction.
Anticancer Res 2006, 26:3685–3692.
24. Kaibori M, Tanigawa N, Kariya S, et al: A prospective randomized
controlled trial of preoperative whole-liver chemolipiodolization for
hepatocellular carcinoma. Dig Dis Sci 2012, 57:1404–1412.
25. Gerunda GE, Neri D, Merenda R, et al: Role of transarterial
chemoembolization before liver resection for hepatocarcinoma.
Liver Transpl 2000, 6:619–626.
26. Zhang Z, Liu Q, He J, et al: The effect of preoperative transcatheter
hepatic arterial chemoembolization on disease-free survival after
hepatectomy for hepatocellular carcinoma. Cancer 2000, 89:2606–2612.
27. Luo YQ, Wang Y, Chen H, et al: Influence of preoperative transcatheter
arterial chemoembolization on liver resection in patients with resectable
hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002, 1:523–526.
28. Harada T, Matsuo K, Inoue T, et al: Is preoperative hepatic arterial
chemoembolization safe and effective for hepatocellular carcinoma?
Ann Surg 1996, 224:4–9.
29. Uchida M, Kohno H, Kubota H, et al: Role of preoperative transcatheter
arterial oily chemoembolization for resectable hepatocellular carcinoma.
World J Surg 1996, 20:326–331.
30. Paye F, Jagot P, Vilgrain V, et al: Preoperative chemoembolization of
hepatocellular carcinoma: a comparative study. Arch Surg 1998,
133:767–772.
Zhou et al. BMC Gastroenterology 2013, 13:51 Page 11 of 11
http://www.biomedcentral.com/1471-230X/13/5131. Lu CD, Peng SY, Jiang XC, et al: Preoperative transcatheter arterial
chemoembolization and prognosis of patients with hepatocellular
carcinomas: retrospective analysis of 120 cases. World J Surg 1999,
23:293–300.
32. Ochiai T, Sonoyama T, Hironaka T, et al: Hepatectomy with
chemoembolization for treatment of hepatocellular carcinoma.
Hepatogastroenterol 2003, 50:750–755.
33. Sugo H, Futagawa S, Beppu T, et al: Role of preoperative transcatheter
arterial chemoembolization for resectable hepatocellular carcinoma:
relation between postoperative course and the pattern of tumor
recurrence. World J Surg 2003, 27:1295–1299.
34. Sasaki A, Iwashita Y, Shibata K, et al: Preoperative transcatheter arterial
chemoembolization reduces long-term survival rate after hepatic
resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 2006,
32:773–779.
35. Chen XP, Hu DY, Zhang ZW, et al: Role of mesohepatectomy with or
without transcatheter arterial chemoembolization for large centrally
located hepatocellular carcinoma. Dig Surg 2007, 24:208–213.
36. Choi GH, Kim DH, Kang CM, et al: Is preoperative transarterial
chemoembolization needed for a resectable hepatocellular carcinoma?
World J Surg 2007, 31:2370–2377.
37. Kim IS, Lim YS, Lee HC, et al: Pre-operative transarterial
chemoembolization for resectable hepatocellular carcinoma adversely
affects post-operative patient outcome. Aliment Pharmacol Ther 2008,
27:338–345.
38. Lee KT, Lu YW, Wang SN, et al: The effect of preoperative transarterial
chemoembolization of resectable hepatocellular carcinoma on clinical
and economic outcomes. J Surg Oncol 2009, 99:343–350.
39. Kang JY, Choi MS, Kim SJ, et al: Long-term outcome of preoperative
transarterial chemoembolization and hepatic resection in patients with
hepatocellular carcinoma. Korean J Hepatol 2010, 16:383–388.
40. Yamashita YI, Takeishi K, Tsuijita E, et al: Beneficial effects of preoperative
lipiodolization for resectable large hepatocellular carcinoma (≥5 cm in
diameter). J Surg Oncol 2012, 106:498–503.
41. Llovet JM, Bruix J: Systematic review of randomized trials for
unresectable hepatocellular carcinoma: chemoembolization improves
survival. Hepatology 2003, 37:429–442.
42. Bruix J, Llovet JM, Castells A, et al: Transarterial embolization versus
symptomatic treatment in patients with advanced hepatocellular
carcinoma: results of a randomized, controlled trial in a single
institution. Hepatology 1998, 27:1578–1583.
43. Ikeda K, Saitoh S, Tsubota A, et al: Risk factors for tumor recurrence and
prognosis after curative resection of hepatocellular carcinoma.
Cancer 1993, 71:19–25.
44. Huang J, He X, Lin X, et al: Effect of preoperative transcatheter arterial
chemoembolization on tumor cell activity in hepatocellular carcinoma.
Chin Med J 2000, 113:446–448.
45. Liou TC, Shih SC, Kao CR, et al: Pulmonary metastasis of hepatocellular
carcinoma associated with transarterial chemoembolization. J Hepatol
1995, 23:563–568.
46. Bonfil RD, Bustuoabad OD, Ruggiero RA, et al: Tumor necrosis can facilitate
the appearance of metastases. Clin Exp Metastasis 1988, 6:121–129.
47. Xiao EH, Li JQ, Huang JF: Effects of p53 on apoptosis and proliferation of
hepatocellular carcinoma cells treated with transcatheter arterial
chemoembolization. World J Gastroenterol 2004, 10:190–194.
48. Xiao EH, Guo D, Bian DJ: Effect of preoperative transcatheter arterial
chemoembolization on angiogenesis of hepatocellular carcinoma cells.
World J Gastroenterol 2009, 15:4582–4586.
doi:10.1186/1471-230X-13-51
Cite this article as: Zhou et al.: Meta-analysis: preoperative transcatheter
arterial chemoembolization does not improve prognosis of patients
with resectable hepatocellular carcinoma. BMC Gastroenterology 2013
13:51.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
